Therefore, the dual inhibitory actions of TIP on MYO6 activity and on LTB4 production could interfere with two independent mechanisms of tumorigenesis, thereby providing an attractive possibility of using this compound for the development of novel anticancer treatment in CRC. Here, MYO6 is linked to colorectal carcinoma.